Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Despite its unparalleled merits for prostate cancer detection and staging, prostate-specific antigen (PSA) is not a marker for prostate cancer only, but also is expressed in benign conditions. For early detection, limitations of PSA are obvious. Its widespread use has led to an extensive amount of e...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Haese, A, Graefen, M, Huland, H, Lilja, H
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2004

Παρόμοια τεκμήρια

[Isoforms of free prostate-specific antigen]
ανά: Haese, A, κ.ά.
Έκδοση: (2004)

Isoforms of free prostate-specific antigen
ανά: Haese, A, κ.ά.
Έκδοση: (2004)

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
ανά: Steuber, T, κ.ά.
Έκδοση: (2002)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
ανά: Haese, A, κ.ά.
Έκδοση: (2003)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
ανά: Haese, A, κ.ά.
Έκδοση: (2003)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
ανά: Steuber, T, κ.ά.
Έκδοση: (2005)

Prediction of tumor heterogeneity in localized prostate cancer.
ανά: Huland, H, κ.ά.
Έκδοση: (2002)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
ανά: Botchorishvili, G, κ.ά.
Έκδοση: (2009)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
ανά: Haese, A, κ.ά.
Έκδοση: (2000)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
ανά: Steuber, T, κ.ά.
Έκδοση: (2007)

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
ανά: Aalamian, M, κ.ά.
Έκδοση: (2003)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
ανά: Steuber, T, κ.ά.
Έκδοση: (2007)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
ανά: Lilja, H, κ.ά.
Έκδοση: (2008)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
ανά: Haese, A, κ.ά.
Έκδοση: (2003)

Biology of prostate-specific antigen
ανά: Lilja, H
Έκδοση: (2003)

Biology of prostate-specific antigen.
ανά: Lilja, H
Έκδοση: (2003)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
ανά: Haese, A, κ.ά.
Έκδοση: (2005)

Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.
ανά: Végvári, A, κ.ά.
Έκδοση: (2010)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
ανά: Vickers, A, κ.ά.
Έκδοση: (2011)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
ανά: Haese, A, κ.ά.
Έκδοση: (2001)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
ανά: Bangma, C, κ.ά.
Έκδοση: (2010)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
ανά: Vickers, A, κ.ά.
Έκδοση: (2009)

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
ανά: Denmeade, SR, κ.ά.
Έκδοση: (2003)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
ανά: Denmeade, SR, κ.ά.
Έκδοση: (2003)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
ανά: Lilja, H, κ.ά.
Έκδοση: (2008)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
ανά: Aus, G, κ.ά.
Έκδοση: (2004)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
ανά: Vickers, A, κ.ά.
Έκδοση: (2010)

Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer
ανά: Azmi A Haroun, κ.ά.
Έκδοση: (2011-01-01)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
ανά: Cao, Y, κ.ά.
Έκδοση: (2002)

Prostatic specific antigen for prostate cancer detection
ανά: Lucas Nogueira, κ.ά.
Έκδοση: (2009-10-01)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
ανά: Becker, C, κ.ά.
Έκδοση: (2001)

Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?
ανά: Jun Seok Kim, κ.ά.
Έκδοση: (2015-04-01)

Prostate-Specific antigen: An overview and its current status in the diagnosis of prostate cancer
ανά: Siddalingeshwar Neeli, κ.ά.
Έκδοση: (2021-01-01)

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
ανά: Zh. R. Cherkasova, κ.ά.
Έκδοση: (2023-03-01)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
ανά: Evans-Axelsson, S, κ.ά.
Έκδοση: (2012)

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
ανά: Nurmikko, P, κ.ά.
Έκδοση: (2002)

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
ανά: Blijenberg, BG, κ.ά.
Έκδοση: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
ανά: Becker, C, κ.ά.
Έκδοση: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
ανά: Becker, C, κ.ά.
Έκδοση: (2003)

Prostate-specific Antigen as a Predictor for the Diagnosis of Prostate Adenocarcinoma
ανά: Wilfredo Valiente Morejón, κ.ά.
Έκδοση: (2015-11-01)